Welcome to our dedicated page for ALLURION TECHNOLOGIES news (Ticker: ALUR), a resource for investors and traders seeking the latest updates and insights on ALLURION TECHNOLOGIES stock.
Allurion Technologies, Inc. (NYSE: ALUR) is a medical device company focused on metabolically healthy weight loss through its Allurion Program and Allurion Smart Capsule. This news page aggregates company press releases and third-party coverage so readers can review how Allurion communicates progress on its weight-loss platform, clinical studies, regulatory milestones, and capital markets activity over time.
Company announcements frequently highlight developments related to the Allurion Smart Capsule, described as the world’s first and only swallowable, Procedureless™ gastric balloon for weight loss, and the Allurion Virtual Care Suite, which includes the Allurion Mobile App, Allurion Insights with the Iris AI Platform, and the Allurion Connected Scale. News items also cover the company’s strategic focus on metabolically healthy weight loss, including combination approaches with low-dose GLP-1 therapies and efforts to maintain or increase lean body mass in patients with overweight and obesity.
Investors and observers can use this page to follow updates on clinical evidence, such as peer-reviewed publications and case series involving the Smart Capsule, lifestyle interventions, and GLP-1 combination therapy. Allurion’s releases describe multicenter studies, case-controlled analyses, and outcomes related to weight reduction, fat mass loss, visceral fat loss, and body composition.
In addition, Allurion’s news flow includes regulatory and financial milestones, including progress in the FDA PMA process for the Allurion Smart Capsule, FDA inspections, Day-100 meetings, private placements of equity and warrants, and transactions to exchange outstanding debt for convertible preferred equity. Readers interested in ALUR news can consult this feed to see how the company reports on its operating strategy, financial results, and key risk disclosures over time.
Allurion (NYSE: ALUR) announced a partnership with Bionut and pharmacy partner Farmastar in Argentina to offer discounted Mounjaro (tirzepatide) for use with the Allurion Smart Capsule, expanding access to combination therapy.
Reported clinical results in 76 patients showed 23% average total body weight loss at 12 months, a 14% point increase in lean body mass share (62% to 70%), full adherence and no early discontinuations while using low doses (2.5–5.0 mg) of tirzepatide.
Allurion (NYSE: ALUR) announced preliminary, unaudited results for Q4 and full-year 2025. Management expects Q4 revenue of $3.3M–$3.7M, representing a 22%–37% quarter-over-quarter increase, and full-year revenue of approximately $15M. The company reported continued, substantial improvement in operating expenses and operating loss both quarter-over-quarter and versus the prior year. Management highlighted that a new commercial strategy implemented after a 2025 strategic pivot contributed to the quarter's revenue growth and said a potential FDA approval of the Allurion Smart Capsule is possible in 2026.
Allurion (NYSE: ALUR) reported initial results from a 76‑patient case series combining the Allurion Program (Smart Capsule + AI Virtual Care Suite) with low‑dose tirzepatide. Patients started tirzepatide at 2.5 mg, titrated to no greater than 5.0 mg, continued for 8 months, with final measures 2 months after discontinuation (total 12‑month follow‑up). After 12 months average total body weight loss was 23% and lean body mass as a percentage of body weight rose 14% (from 62% to 70%). No patients discontinued early; all remained adherent to tirzepatide. Company plans further data collection and presentation at upcoming medical meetings and aims for a prospective clinical trial.
Allurion Technologies (NYSE: ALUR) announced a peer-reviewed, case-controlled study in 1,143 patients (BMI ≥30 kg/m2) showing the Allurion Smart Capsule plus individualized lifestyle intervention produced an average 20% weight reduction at 36 weeks with greater fat mass and visceral fat loss versus lifestyle intervention alone.
The study reports nearly twice the fat reduction and preserved muscle mass, and the company cites efficacy comparable to bariatric surgery and better real-world high-dose GLP-1 outcomes at a substantially lower cost. The Smart Capsule is swallowed in an outpatient visit, is filled in the stomach, and passes naturally after four months; combined with digital remote care for behavior change.
Allurion (NYSE: ALUR) announced a strategic distribution partnership with ProSurg Medical in Brazil on November 18, 2025 to expand access to its metabolically healthy weight loss program.
The agreement leverages ProSurg's 30 years of local experience and its network across over 300 hospitals to deploy the Allurion Program alongside multidisciplinary teams (dietitians, bariatric surgeons, endoscopic specialists) and to increase combined use with GLP-1 therapy to enhance short- and long-term outcomes.
Allurion (NYSE: ALUR) reported Q3 2025 results on November 12, 2025, with revenue of $2.7M and gross profit $1.3M (49% margin). The company said it passed FDA pre-approval inspection and BIMO audit with zero observations, entered PMA substantive review for the Allurion Smart Capsule and completed the Day-100 meeting. Allurion announced a transaction to exchange outstanding debt for convertible preferred equity and closed a $5M private placement. Q3 operating loss was $9.6M (adjusted loss $6.9M); cash was $6.1M as of September 30, 2025, excluding the private placement.
Allurion (NYSE: ALUR) reported major regulatory and financing developments on November 11, 2025. The company said it passed FDA pre-approval and BIMO inspections with zero findings and completed its Day-100 meeting, with the FDA not requesting additional human clinical data, signaling entry into the final stages of PMA review for the Allurion Smart Capsule.
Allurion also announced an exchange transaction to convert outstanding Revenue Interest Financing debt into Series B convertible preferred stock and a $5 million private placement (2,994,012 shares and warrants at $1.67 per share) to bolster working capital as it pursues FDA approval.
Allurion (NYSE: ALUR) will report third quarter 2025 financial results on Wednesday, November 12, 2025. Management will host a conference call and business update the same day at 8:30 AM ET.
To join by phone dial (888) 330-3417 (domestic) or +1 (646) 960-0804 (international) and use Conference ID 1905455. A live audio webcast will be available in the Events section of Allurion's Investor Relations website and a replay will be available by phone at (800) 770-2030 with Access Code 1905455. The archived webcast will also be posted on the Investor Relations site.
Allurion (NYSE: ALUR) published a multicenter, peer-reviewed retrospective study on October 7, 2025 reporting that two consecutive treatments with the Allurion Smart Capsule produced average 22.1% total body weight loss (19.3 kg) in 121 adults across 11 sites in six countries.
The study reported no serious device-related adverse events, aligns with the company’s FDA pivotal AUDACITY approach, and follows submission of the fourth and final PMA module to the FDA earlier in 2025.
Allurion Technologies (NYSE:ALUR), a company focused on metabolically healthy weight loss, has announced its participation in the upcoming ROTH 4th Annual Healthcare Opportunities Conference. The event will take place on October 9, 2025 at the Metropolitan Club in New York City. The company's management team will be available for one-on-one meetings with investors throughout the conference day.
FAQ
What is the current stock price of ALLURION TECHNOLOGIES (ALUR)?
What is the market cap of ALLURION TECHNOLOGIES (ALUR)?
